E-therapeutics Regulatory News (ETX)

Notification of Half Year Results Date

Oxford and Newcastle, UK - 17 September 2015 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its half year results for the six months ended 31 July 2015 on Tuesday, 29 September 2015.

A group analyst briefing will be held at 11:30am on Tuesday, 29 September 2015 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email e-therapeutics@instinctif.com to register.

-Ends-

Contacts:

e-Therapeutics plc

Malcolm Young, CEO / Steve Medlicott, Finance Director

Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk

Numis Securities Limited

Michael Meade / Freddie Barnfield (Nominated Adviser)

Graeme Summers / James Black (Corporate Broking)

Tel: +44 (0) 20 7260 1000

Instinctif Partners

Melanie Toyne Sewell / Jayne Crook

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is a drug discovery and development company with a proprietary platform in network pharmacology, an innovative approach to drug discovery based on advances in network science and chemical biology. e-Therapeutics' platform is generating more potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery. The Company's discovery and development activity addresses age-related diseases, including cancer and central nervous system disorders, and it is fully funded to advance its programme into 2019, including phase II clinical data and multiple regulatory submissions.

e-Therapeutics has a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103. It has a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The company has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400 and Hedgehog pathway inhibition.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.